Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19

Devang K. Sanghavi; Anoop Titus; Thomas R. Caulfield; W. David Freeman

doi:10.1016/j.mehy.2021.110564

Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19

Devang K. Sanghavi, Anoop Titus, Thomas R. Caulfield, W. David Freeman

Neuroscience

Research output: Contribution to journal › Article › peer-review

Abstract

We summarize the role of endothelin as a potent vasoconstrictor, pro-inflammatory, pro-oxidative agent in the pathophysiologic effects and end-organ dysfunction of coronavirus disease 2019 (COVID-19). Endotheliitis is an under-recognized pathophysiologic process that causes various types of dysfunction in end organs, including heart, lung, kidney, and brain. Endothelin receptor blockers, such as bosentan and sitaxentan, can pave a path ahead in the realm of COVID-19 therapies. These agents have a potential role against COVID-19 and should be studied in research trials to determine their efficacy in treatment of this severe disease.

Original language	English (US)
Article number	110564
Journal	Medical Hypotheses
Volume	150
DOIs	https://doi.org/10.1016/j.mehy.2021.110564
State	Published - May 2021

Keywords

Bosentan
COVID-19
Endotheliitis
Endothelin
Endothelin receptor blockers
Sitaxentan

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/j.mehy.2021.110564

Cite this

@article{9375d7bc15df4cef85f4833677afa4eb,

title = "Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19",

abstract = "We summarize the role of endothelin as a potent vasoconstrictor, pro-inflammatory, pro-oxidative agent in the pathophysiologic effects and end-organ dysfunction of coronavirus disease 2019 (COVID-19). Endotheliitis is an under-recognized pathophysiologic process that causes various types of dysfunction in end organs, including heart, lung, kidney, and brain. Endothelin receptor blockers, such as bosentan and sitaxentan, can pave a path ahead in the realm of COVID-19 therapies. These agents have a potential role against COVID-19 and should be studied in research trials to determine their efficacy in treatment of this severe disease.",

keywords = "Bosentan, COVID-19, Endotheliitis, Endothelin, Endothelin receptor blockers, Sitaxentan",

author = "Sanghavi, {Devang K.} and Anoop Titus and Caulfield, {Thomas R.} and {David Freeman}, W.",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = may,

doi = "10.1016/j.mehy.2021.110564",

language = "English (US)",

volume = "150",

journal = "Medical Hypotheses",

issn = "0306-9877",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19

AU - Sanghavi, Devang K.

AU - Titus, Anoop

AU - Caulfield, Thomas R.

AU - David Freeman, W.

PY - 2021/5

Y1 - 2021/5

N2 - We summarize the role of endothelin as a potent vasoconstrictor, pro-inflammatory, pro-oxidative agent in the pathophysiologic effects and end-organ dysfunction of coronavirus disease 2019 (COVID-19). Endotheliitis is an under-recognized pathophysiologic process that causes various types of dysfunction in end organs, including heart, lung, kidney, and brain. Endothelin receptor blockers, such as bosentan and sitaxentan, can pave a path ahead in the realm of COVID-19 therapies. These agents have a potential role against COVID-19 and should be studied in research trials to determine their efficacy in treatment of this severe disease.

AB - We summarize the role of endothelin as a potent vasoconstrictor, pro-inflammatory, pro-oxidative agent in the pathophysiologic effects and end-organ dysfunction of coronavirus disease 2019 (COVID-19). Endotheliitis is an under-recognized pathophysiologic process that causes various types of dysfunction in end organs, including heart, lung, kidney, and brain. Endothelin receptor blockers, such as bosentan and sitaxentan, can pave a path ahead in the realm of COVID-19 therapies. These agents have a potential role against COVID-19 and should be studied in research trials to determine their efficacy in treatment of this severe disease.

KW - Bosentan

KW - COVID-19

KW - Endotheliitis

KW - Endothelin

KW - Endothelin receptor blockers

KW - Sitaxentan

UR - http://www.scopus.com/inward/record.url?scp=85103930727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103930727&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2021.110564

DO - 10.1016/j.mehy.2021.110564

M3 - Article

C2 - 33823371

AN - SCOPUS:85103930727

SN - 0306-9877

VL - 150

JO - Medical Hypotheses

JF - Medical Hypotheses

M1 - 110564

ER -

Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this